Novoprotein Scientific Inc. (SHA:688137)

Novoprotein Scientific Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	734.35	711.1	647.35	863.7	929.92	189.39
Short-Term Investments	-	998.93	1,154	404.51	-	-
Trading Asset Securities	100.42	-	-	621.7	966.85	-
Cash & Short-Term Investments	834.77	1,710	1,801	1,890	1,897	189.39
Cash Growth	-52.69%	-5.07%	-4.69%	-0.36%	901.50%	101.86%
Accounts Receivable	62.12	61.77	62.02	79.97	134.66	96.58
Other Receivables	5.39	8.55	10.91	3.45	10.35	2.95
Receivables	67.52	70.32	72.93	83.42	145	99.53
Inventory	76.53	63.32	76.08	84.97	77.08	37.19
Other Current Assets	838.85	11.3	5.95	11.9	16.29	6.11
Total Current Assets	1,818	1,855	1,956	2,070	2,135	332.22
Property, Plant & Equipment	214.46	216.42	170.14	133.92	134.98	137.95
Long-Term Investments	13	10	10	-	-	-
Other Intangible Assets	17.51	17.77	18.21	18.71	18.18	6.71
Long-Term Deferred Tax Assets	23.4	23.81	31.22	27.94	18.51	12.96
Long-Term Deferred Charges	49.29	6.61	10.78	9.69	5.6	4.93
Other Long-Term Assets	3.55	21.98	21.48	38.45	21.05	18.33
Total Assets	2,139	2,152	2,218	2,299	2,333	513.1

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	65.27	36.23	28.26	17.94	20.9	23.64
Accrued Expenses	14.15	15.76	14.82	11.82	18.03	21.21
Current Portion of Leases	-	10	17.67	13.87	13.95	8.69
Current Income Taxes Payable	0.48	-	0.01	1.34	5.01	4.52
Current Unearned Revenue	5.18	5.85	5.02	4.19	4.81	11.61
Other Current Liabilities	2.52	1.29	1.39	0.97	1.32	2.11
Total Current Liabilities	96.87	69.12	67.17	50.12	64.02	71.78
Long-Term Leases	41.1	45.6	48.75	59.44	69.2	78.34
Long-Term Unearned Revenue	1.46	1.55	0.52	0.87	-	-
Long-Term Deferred Tax Liabilities	-	-	-	-	-	3.21
Other Long-Term Liabilities	0.92	0.55	-	-	-	-
Total Liabilities	140.36	116.83	116.44	110.43	133.22	153.33

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	69.92	70.18	70.18	70.18	70.18	52.63
Additional Paid-In Capital	1,969	1,976	1,963	1,950	1,940	208.13
Retained Earnings	-28.63	0.57	78.36	167.86	190.1	98.82
Treasury Stock	-11.96	-11.96	-10.35	-	-	-
Comprehensive Income & Other	0.54	0.27	0.15	0.18	0.18	0.19
Shareholders' Equity	1,999	2,035	2,102	2,188	2,200	359.77
Total Liabilities & Equity	2,139	2,152	2,218	2,299	2,333	513.1

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	50.37	55.61	66.42	73.31	83.15	87.04
Net Cash (Debt)	784.4	1,654	1,735	1,817	1,814	102.36
Net Cash Growth	-54.12%	-4.64%	-4.50%	0.16%	1671.86%	9.09%
Net Cash Per Share	11.17	23.61	24.87	25.46	31.79	2.56
Filing Date Shares Outstanding	68.37	69.77	69.83	70.18	70.18	52.63
Total Common Shares Outstanding	68.37	69.77	69.83	70.18	70.18	52.63
Working Capital	1,721	1,786	1,889	2,020	2,071	260.44
Book Value Per Share	29.23	29.16	30.10	31.19	31.35	6.84
Tangible Book Value	1,981	2,017	2,083	2,170	2,182	353.06
Tangible Book Value Per Share	28.97	28.91	29.84	30.92	31.09	6.71
Machinery	-	95.2	78.93	64.44	59.66	42.2
Construction In Progress	-	132.22	74.95	31.26	17.73	21.16

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error